Nifurpirinol
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Nifurpirinol
- DrugBank Accession Number
- DB11436
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Vet approved
- Structure
- Weight
- Average: 246.222
Monoisotopic: 246.06405681 - Chemical Formula
- C12H10N2O4
- Synonyms
- Furpyrinol
- Nifurpirinol
- Nifurpirinolum
- External IDs
- NF 323
- P 7138
- P-7138
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Furanace (veterinary)
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as nitrofurans. These are compounds containing a furan ring which bears a nitro group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Furans
- Sub Class
- Nitrofurans
- Direct Parent
- Nitrofurans
- Alternative Parents
- Nitroaromatic compounds / Pyridines and derivatives / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds show 4 more
- Substituents
- 2-nitrofuran / Alcohol / Allyl-type 1,3-dipolar organic compound / Aromatic alcohol / Aromatic heteromonocyclic compound / Azacycle / C-nitro compound / Heteroaromatic compound / Hydrocarbon derivative / Nitroaromatic compound show 14 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7O5A98XY8U
- CAS number
- 13411-16-0
- InChI Key
- JQKHJQJVKRFMCO-SNAWJCMRSA-N
- InChI
- InChI=1S/C12H10N2O4/c15-8-10-3-1-2-9(13-10)4-5-11-6-7-12(18-11)14(16)17/h1-7,15H,8H2/b5-4+
- IUPAC Name
- {6-[(1E)-2-(5-nitrofuran-2-yl)ethenyl]pyridin-2-yl}methanol
- SMILES
- [H]\C(=C(\[H])C1=NC(CO)=CC=C1)C1=CC=C(O1)[N+]([O-])=O
References
- General References
- Nakamura Y, Fukushima H, Tomita I, Kimura I: Mutagenicity of nifurpirinol (P-7138) in Escherichia coli WP2 and Salmonella typhimurium TA100. Mutat Res. 1982 Apr;104(1-3):61-6. [Article]
- Takase Y, Nakamura S, Ishiyama M, Shimizu M: Inhibition of the synthesis of macromolecules in Escherichia coli by nitrofuran derivatives. 3. Nifurpirinol. Chem Pharm Bull (Tokyo). 1973 Jan;21(1):144-8. [Article]
- Tamse CT, Gacutan RQ: Acute toxicity of nifurpirinol, a fish chemotherapeutant, to milkfish (Chanos chanos) fingerlings. Bull Environ Contam Toxicol. 1994 Mar;52(3):346-50. [Article]
- Tamse CT, Gacutan RQ, Tamse AF: Changes induced in the gills of milkfish (Chanos chanos Forsskal) fingerlings after acute exposure to nifurpirinol (Furanace; P-7138). Bull Environ Contam Toxicol. 1995 Apr;54(4):591-6. [Article]
- MacMillan JR, Schnick RA, Fornshell G: Stakeholder position paper: aquaculture producer. Prev Vet Med. 2006 Feb 24;73(2-3):197-202. Epub 2005 Nov 9. [Article]
- Kimura I, Kinae N, Kumai H, Yamashita M, Nakamura G, Ando M, Ishida H, Tomita I: Environment: peculiar pigment cell neoplasm in fish. J Invest Dermatol. 1989 May;92(5 Suppl):248S-254S. [Article]
- Ferguson HW, Moccia RD: Disseminated hexamitiasis in Siamese fighting fish. J Am Vet Med Assoc. 1980 Nov 1;177(9):854-7. [Article]
- Kimura I, Taniguchi N, Kumai H, Tomita I, Kinae N, Yoshizaki K, Ito M, Ishikawa T: Correlation of epizootiological observations with experimental data: chemical induction of chromatophoromas in the croaker, Nibea mitsukurii. Natl Cancer Inst Monogr. 1984 May;65:139-54. [Article]
- Declercq AM, Haesebrouck F, Van den Broeck W, Bossier P, Decostere A: Columnaris disease in fish: a review with emphasis on bacterium-host interactions. Vet Res. 2013 Apr 24;44:27. doi: 10.1186/1297-9716-44-27. [Article]
- Nose N, Hoshino Y, Kikuchi Y, Horie M, Saitoh K, Kawachi T, Nakazawa H: Simultaneous liquid chromatographic determination of residual synthetic antibacterials in cultured fish. J Assoc Off Anal Chem. 1987 Jul-Aug;70(4):714-7. [Article]
- External Links
- KEGG Drug
- D02513
- ChemSpider
- 4940737
- ChEBI
- 135000
- ChEMBL
- CHEMBL2104627
- ZINC
- ZINC000004217117
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0919 mg/mL ALOGPS logP 1.9 ALOGPS logP 1.73 Chemaxon logS -3.4 ALOGPS pKa (Strongest Acidic) 14.22 Chemaxon pKa (Strongest Basic) 4.16 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 89.4 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 63.17 m3·mol-1 Chemaxon Polarizability 24.53 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-004m-0960000000-8cc4e62c4cce894f839b Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 174.2995704 predictedDarkChem Lite v0.1.0 [M-H]- 164.33534 predictedDeepCCS 1.0 (2019) [M+H]+ 174.1288704 predictedDarkChem Lite v0.1.0 [M+H]+ 166.69371 predictedDeepCCS 1.0 (2019) [M+Na]+ 174.1705704 predictedDarkChem Lite v0.1.0 [M+Na]+ 173.0694 predictedDeepCCS 1.0 (2019)
Drug created at February 25, 2016 18:46 / Updated at February 21, 2021 18:53